Supriya Lifescience Ltd (SUPRIYA) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company demonstrated robust performance with an 11% year-on-year revenue growth, driven by strong demand across its product portfolio.
- Operational efficiency and a focus on high-margin niche products resulted in strong profitability, achieving a 34.9% EBITDA margin and a 24.1% PAT margin for the quarter.
- Exports remained a significant growth engine, contributing 82% of the quarterly revenue, with the LATAM region showing particularly healthy growth and accounting for 24% of total revenues.
- Strategic initiatives progressed well, with the successful launch of a key cardiovascular product and an ADHD product, which are expected to contribute meaningfully in the coming quarters.
- A major milestone was achieved with the Ambernath facility being ready for commissioning, positioning the company to capitalize on its CDMO segment opportunities starting in Q4 FY26.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.